On October 26, 2020 Catabasis announced that the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy did not meet its primary or secondary endpoints. Catabasis joined PPMD for a webinar on October 27, 2020 to discuss the trial and results in more detail, as well as the company’s plans for the edasalonexent program going forward.
by: Parent Project Muscular Dystrophy
